HK Stock Market Move | RIBOLIFE-B (06938) rose nearly 4% during the trading session, and it is expected to achieve a year-on-year revenue growth of at least approximately 200% to 320% in the first half of the year.

RIBOLIFE-B (06938) surged nearly 4% during the trading session, and as of the time of writing, it is up 3.47%, priced at HKD 48.26, with a transaction volume of HKD 1.7086 million. In terms of news, RIBOLIFE-B recently released an announcement indicating that the group anticipates revenue of approximately HKD 311 million to HKD 436 million in the first half of 2026, representing an increase of about 200% to 320% compared to the same period in 2025. This growth is primarily attributed to the recognition of licensing income under the global exclusive licensing collaboration between the group and Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), along with income recognized upon achieving milestones in the collaboration with Boehringer Ingelheim International GmbH. Both collaborations relate to the development and commercialization of small interfering RNA (siRNA) therapies for metabolic dysfunction-associated steatotic liver disease (MASH) and are the main drivers of the group's revenue growth during the reporting period.